Category: Press Release - Psilocybin Alpha

New Resource: Psychedelic Legalization & Decriminalization Tracker

PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors

PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors

Post published:September 24, 2021
Post category:Press Release

Levitee Labs Announces DTC Eligibility Approval

Levitee Labs Announces DTC Eligibility Approval

Post published:September 24, 2021
Post category:Press Release

Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London

Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London

Post published:September 23, 2021
Post category:Press Release

Numinus Completes Acquisition of Neurology Centre of Toronto

Numinus Completes Acquisition of Neurology Centre of Toronto

Post published:September 23, 2021
Post category:Press Release

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Post published:September 23, 2021
Post category:Press Release

ATMA Journey Centers Offer Regulated Health Care Professionals a Means to Incorporate Psychedelic-Assisted Psychotherapy Into Their Practice

ATMA Journey Centers Offer Regulated Health Care Professionals a Means to Incorporate Psychedelic-Assisted Psychotherapy Into Their Practice

Post published:September 23, 2021
Post category:Press Release

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

Post published:September 23, 2021
Post category:Press Release

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Post published:September 22, 2021
Post category:Press Release

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders

Post published:September 22, 2021
Post category:Press Release

Bright Minds Biosciences Provides Scientific Update

Bright Minds Biosciences Provides Scientific Update

Post published:September 22, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.